PRIMARY STUDY
Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment
Key Findings: In dogs with osteoarthritis, cannabis extract did not significantly reduce pain scores, but was safe and without significant adverse effects.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Brazil
Year of Pub: 2025
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabinol (CBN), Cannabidiolic Acid (CBD-a), Cannabigerolic Acid (CBG-a), Tetrahydrocannabinolic Acid (THC-a), Cannabinoid (unspecified), Tetrahydrocannabivarin (THCV), Delta-8-THC, Cannabidivarin (CBDV)
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: No effective dose
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (CBD : THC : CBC) 780 : 30 : 36 
Dosage Form: Full-spectrum cannabis oil
Dosing Regimen: Twice daily dosing. Total daily dose: 7.8 mg/kg of CBD 0.30 mg/kg of THC 0.36 mg/kg of CBC 0.28 mg/kg of CBGA 0.18 mg/kg of CBG other cannabinoids
Treatment Duration: 90 days
Clinical Relevance: Pain was reduced, but it was not statistically significant. The cannabis extract product was well-tolerated.
Adverse Events: Diarrhea was the most frequent Anxiety and hyperphagia were the only adverse events that reached statistical significance
Citation: Griebeler NM, Cremonese RP, Fakih Correa YR, Pereira PRM, Rial AF, Leite E, Gonçalves MVL, Marques das Almas LR, Cardoso NB, Cezar-Dos-Santos F, Toci AT, Mojoli Le-Quesne A, Nascimento FP. Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. Front Pharmacol. 2025 Nov 24;16:1539704. doi: 10.3389/fphar.2025.1539704. Erratum in: Front Pharmacol. 2026 Jan 20;16:1758996. doi: 10.3389/fphar.2025.1758996. PMID: 41368581; PMCID: PMC12682811.
